Ciro Franzese1,2, Lucia Di Brina3, Giuseppe D'Agostino3, Davide Franceschini3, Tiziana Comito3, Fiorenza De Rose3, Angelo Tozzi3, Pierina Navarria3, Marta Scorsetti3,4. 1. Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Hospital, IRCCS, Via Manzoni 56, Milan, Rozzano, Italy. ciro.franzese@humanitas.it. 2. Department of Biomedical Sciences, Humanitas University, Milan, Rozzano, Italy. ciro.franzese@humanitas.it. 3. Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Hospital, IRCCS, Via Manzoni 56, Milan, Rozzano, Italy. 4. Department of Biomedical Sciences, Humanitas University, Milan, Rozzano, Italy.
Abstract
PURPOSE: The aim of the present study was to provide predictive factors for survival outcomes of oligometastatic prostate cancer (PC) patients treated with stereotactic body radiation therapy (SBRT) as a metastases-directed therapy (MDT). METHODS: In this cohort study, endpoints included overall survival (OS), progression-free survival (PFS), distant progression-free survival (DFS) and local control of treated metastases (LC). The binary classification tree approach with recursive partitioning analysis (RPA) was applied to stratify the patients into risk groups based on OS, PFS and DPFS; for each endpoint, disease-free interval (DFI) was calculated. We included patients with synchronous or metachronous metastases from prostate adenocarcinoma treated with SBRT. RESULTS: 119 Metastases were treated with SBRT in 92 patients. Median follow-up was 22.2 months. Rates of OS at 1 and 3 years were 96.9% and 88.0%, while DPFS was 51.9% and 20.9%. Recursive partitioning analysis identified three prognostic classes for OS: Class 1: castration-sensitive patients (3 years OS 95%); Class 2: castration-resistant patients with low-intermediate risk NCCN disease (3 years OS 88.8%); Class 3: castration-resistant patients with high-risk NCCN disease (3 years OS 76.9%). Regarding DPFS, RPA divided patients into two classes, according to a cutoff value of DFI of 34 months (3 years PFS of 28.7% vs 5.8%). Three classes were identified for DPFS: Class 1: DFI < 34 months (3 years DPFS 9.1%); Class 2: DFI > 34 months and high-risk NCCN PC (3 years DPFS 21%); Class 3: DFI > 34 months and low-intermediate risk NCCN disease (3 years DPFS 60.2%). CONCLUSION: Oligometastatic PC represents nowadays a setting of particular interest in which local ablative therapies play a decisive role. In the present study, we recognized the importance of DFI, together with NCCN class risk, to predict the risk of new metastases after SBRT in oligometastatic PC.
PURPOSE: The aim of the present study was to provide predictive factors for survival outcomes of oligometastatic prostate cancer (PC) patients treated with stereotactic body radiation therapy (SBRT) as a metastases-directed therapy (MDT). METHODS: In this cohort study, endpoints included overall survival (OS), progression-free survival (PFS), distant progression-free survival (DFS) and local control of treated metastases (LC). The binary classification tree approach with recursive partitioning analysis (RPA) was applied to stratify the patients into risk groups based on OS, PFS and DPFS; for each endpoint, disease-free interval (DFI) was calculated. We included patients with synchronous or metachronous metastases from prostate adenocarcinoma treated with SBRT. RESULTS: 119 Metastases were treated with SBRT in 92 patients. Median follow-up was 22.2 months. Rates of OS at 1 and 3 years were 96.9% and 88.0%, while DPFS was 51.9% and 20.9%. Recursive partitioning analysis identified three prognostic classes for OS: Class 1: castration-sensitive patients (3 years OS 95%); Class 2: castration-resistant patients with low-intermediate risk NCCN disease (3 years OS 88.8%); Class 3: castration-resistant patients with high-risk NCCN disease (3 years OS 76.9%). Regarding DPFS, RPA divided patients into two classes, according to a cutoff value of DFI of 34 months (3 years PFS of 28.7% vs 5.8%). Three classes were identified for DPFS: Class 1: DFI < 34 months (3 years DPFS 9.1%); Class 2: DFI > 34 months and high-risk NCCN PC (3 years DPFS 21%); Class 3: DFI > 34 months and low-intermediate risk NCCN disease (3 years DPFS 60.2%). CONCLUSION: Oligometastatic PC represents nowadays a setting of particular interest in which local ablative therapies play a decisive role. In the present study, we recognized the importance of DFI, together with NCCN class risk, to predict the risk of new metastases after SBRT in oligometastatic PC.
Authors: Aurélie De Bruycker; Bieke Lambert; Tom Claeys; Louke Delrue; Chamberlain Mbah; Gert De Meerleer; Geert Villeirs; Filip De Vos; Kathia De Man; Karel Decaestecker; Valérie Fonteyne; Nicolaas Lumen; Filip Ameye; Ignace Billiet; Steven Joniau; Friedl Vanhaverbeke; Wim Duthoy; Piet Ost Journal: BJU Int Date: 2017-07-16 Impact factor: 5.588
Authors: Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Roger Kockelbergh; Howard Kynaston; Alan Paul; Philip Powell; Stephen Prescott; Derek J Rosario; Edward Rowe; David E Neal Journal: N Engl J Med Date: 2016-09-14 Impact factor: 91.245
Authors: Lars Holmberg; Anna Bill-Axelson; Fred Helgesen; Jaakko O Salo; Per Folmerz; Michael Häggman; Swen-Olof Andersson; Anders Spångberg; Christer Busch; Steg Nordling; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson; Bo Johan Norlén Journal: N Engl J Med Date: 2002-09-12 Impact factor: 91.245
Authors: Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså Journal: Lancet Date: 2008-12-16 Impact factor: 79.321
Authors: Piet Ost; Alberto Bossi; Karel Decaestecker; Gert De Meerleer; Gianluca Giannarini; R Jeffrey Karnes; Mack Roach; Alberto Briganti Journal: Eur Urol Date: 2014-09-17 Impact factor: 20.096
Authors: Karim Fizazi; NamPhuong Tran; Luis Fein; Nobuaki Matsubara; Alfredo Rodriguez-Antolin; Boris Y Alekseev; Mustafa Özgüroğlu; Dingwei Ye; Susan Feyerabend; Andrew Protheroe; Peter De Porre; Thian Kheoh; Youn C Park; Mary B Todd; Kim N Chi Journal: N Engl J Med Date: 2017-06-04 Impact factor: 91.245
Authors: Karel Decaestecker; Gert De Meerleer; Bieke Lambert; Louke Delrue; Valérie Fonteyne; Tom Claeys; Filip De Vos; Wouter Huysse; Arne Hautekiet; Gaethan Maes; Piet Ost Journal: Radiat Oncol Date: 2014-06-12 Impact factor: 3.481
Authors: Julian C Hong; Diandra N Ayala-Peacock; Jason Lee; A William Blackstock; Paul Okunieff; Max W Sung; Ralph R Weichselbaum; Johnny Kao; James J Urbanic; Michael T Milano; Steven J Chmura; Joseph K Salama Journal: PLoS One Date: 2018-04-12 Impact factor: 3.240
Authors: Ciro Franzese; Paolo Andrea Zucali; Lucia Di Brina; Giuseppe D'Agostino; Pierina Navarria; Davide Franceschini; Armando Santoro; Marta Scorsetti Journal: Cancer Med Date: 2018-08-02 Impact factor: 4.452
Authors: C Reverberi; M Massaro; M F Osti; D Anzellini; L Marinelli; A Montalto; V De Sanctis; M Valeriani Journal: Sci Rep Date: 2020-10-15 Impact factor: 4.379
Authors: Paul Rogowski; Mack Roach; Nina-Sophie Schmidt-Hegemann; Christian Trapp; Rieke von Bestenbostel; Run Shi; Alexander Buchner; Christian Stief; Claus Belka; Minglun Li Journal: Radiat Oncol Date: 2021-03-09 Impact factor: 3.481
Authors: Goda Kalinauskaite; Carolin Senger; Anne Kluge; Christian Furth; Markus Kufeld; Ingeborg Tinhofer; Volker Budach; Marcus Beck; Alexandra Hochreiter; Arne Grün; Carmen Stromberger Journal: PLoS One Date: 2020-10-21 Impact factor: 3.240